Neogen Corp's shares surged by 30.76%, crossing above the 5-day SMA, despite the broader market decline with the Nasdaq-100 down 0.74% and the S&P 500 down 0.08%.
The stock's significant rise is attributed to Neogen's announcement of a $15.9 million net loss for Q2, which, while concerning, showed a marked improvement from the previous year's loss. Additionally, the company raised its full-year revenue outlook for fiscal year 2026, projecting revenues between $845 million and $855 million, reflecting confidence in future growth prospects.
This optimistic outlook, despite the reported loss, suggests that investors are focusing on the company's potential for recovery and growth, indicating a shift in market sentiment towards Neogen's long-term strategy.
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.350
Low
6.50
Averages
8.17
High
10.00
Current: 10.350
Low
6.50
Averages
8.17
High
10.00
Guggenheim
Buy
maintain
$8 -> $12
2026-01-09
Reason
Guggenheim
Price Target
$8 -> $12
AI Analysis
2026-01-09
maintain
Buy
Reason
Guggenheim raised the firm's price target on Neogen to $12 from $8 and keeps a Buy rating on the shares after the company beat revenue and EBITDA expectations and raised guidance. While stating that one quarter "does not make a trend," the firm adds that the portfolio performed well and cost actions "clearly are starting to take hold."
CJS Securities
Robert Labick
Market Perform -> Outperform
upgrade
$10
2025-12-10
Reason
CJS Securities
Robert Labick
Price Target
$10
2025-12-10
upgrade
Market Perform -> Outperform
Reason
CJS Securities analyst Robert Labick upgraded Neogen to Outperform from Market Perform with a $10 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEOG
Unlock Now
Piper Sandler
David Westenberg
Neutral
maintain
$5
2025-10-16
Reason
Piper Sandler
David Westenberg
Price Target
$5
2025-10-16
maintain
Neutral
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on Neogen to $6.50 from $5 following quarterly results. The firm keeps a Neutral rating on the shares.
CJS Securities
initiated
$10
2025-09-29
Reason
CJS Securities
Price Target
$10
2025-09-29
initiated
Reason
CJS Securities initiated coverage of Neogen with a Market Perform rating and $10 price target.
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
